Tuberculosis News and Research

Latest Tuberculosis News and Research

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Video monitoring of TB therapy works well in urban and rural areas

Researchers from University of California San Diego School of Medicine, with statewide collaborators, report that patients who recorded videos of themselves taking tuberculosis medications better adhered to treatment than patients who were observed in-person.

16 Oct 2018

Global health innovation system fails to deliver affordable treatments to patients, says report

NHS patients are being let down by a global health innovation system which fails to deliver the treatments they need at prices that government can afford, according to a new report led by Professor Mariana Mazzucato, Director of the UCL Institute for Innovation and Public Purpose, in collaboration with STOPAIDS, Global Justice Now and Just Treatment.

15 Oct 2018

Healthcare systems fail to deliver at affordable prices finds report

According to a new report from Professor Mariana Mazzucato, Director of the UCL Institute for Innovation and Public Purpose (IIPP), in collaboration with STOPAIDS, Global Justice Now and Just Treatment, the NHS patients are not getting treatments at affordable process and this is a failure on part of the global health innovation system.

15 Oct 2018

Scripps Research scientists discover role of immune system double agent

Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.

5 Oct 2018

UConn chemists develop new antibiotic that can find and kill tuberculosis bacteria

Tuberculosis is a sneaky disease. The bacteria hide from antibiotics inside the very immune cells that are supposed to kill them, making treatment long and difficult. But in the November issue of ACS Infectious Diseases, UConn chemists report a new antibiotic that can find and kill tuberculosis bacteria where they hide.

4 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than one billion people--more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

27 Sep 2018

Diabetes patients with poor blood sugar control face highest risk of serious infections

A new study has shown that diabetes patients with the poorest control of their blood sugars face the highest risks of hospitalization and death due to infections.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms

Alcohol is a leading contributor to death and disability worldwide, but governments haven’t responded to the issue with the attention, resources and action this urgent issue requires, says “Trouble Brewing,” a new report from global health and development organizations, Vital Strategies, the NCD Alliance, IOGT International and the Global Alcohol Policy Alliance.

25 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

New naturally occurring antibiotic found effective against Mycobacterium tuberculosis

A naturally occurring antibiotic called kanglemycin A is effective against Mycobacterium tuberculosis, the bacteria that cause tuberculosis, even in drug-resistant strains, according to an international team of researchers who used chemistry, molecular biology, microbiology, and X-ray crystallography to show how the compound maintains its activity.

21 Sep 2018

LSTM partners with TB Alliance to develop novel TB drug regimens

LSTM and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.

19 Sep 2018

QIAGEN and DiaSorin launch automated, CE-marked workflow for high-throughput TB screening

QIAGEN N.V. and DiaSorin today announced the introduction of an automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test on widely used immunodiagnostic instruments from DiaSorin.

17 Sep 2018

Inhaled steroid use linked to greater risk of NTM lung infections

Patients using inhaled steroids to control asthma and other breathing problems may be at greater risk for developing nontuberculous mycobacteria lung infections, according to new research published online in the Annals of the American Thoracic Society.

17 Sep 2018

Scientists develop first non-antibiotic drug to treat tuberculosis in animals

Scientists at The University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals.

11 Sep 2018

Effective vaccines for world's most prevalent infectious diseases are missing from pipeline

Many of the vaccines critically needed to fight some of the world's most prevalent infectious diseases are not likely to be developed, a new analysis of current candidates in the research and development pipeline has found.

5 Sep 2018

Tuberculosis News and Research

Latest Tuberculosis News and Research

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Video monitoring of TB therapy works well in urban and rural areas

Global health innovation system fails to deliver affordable treatments to patients, says report

Healthcare systems fail to deliver at affordable prices finds report

Scripps Research scientists discover role of immune system double agent

UConn chemists develop new antibiotic that can find and kill tuberculosis bacteria

New ReFRAME drug repurposing collection offers hope for treating major diseases

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Diabetes patients with poor blood sugar control face highest risk of serious infections

New TB vaccine effective in half of the population in phase II trials

‘Trouble Brewing’ report highlights steps that governments can take to reduce alcohol-related harms

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

New naturally occurring antibiotic found effective against Mycobacterium tuberculosis

LSTM partners with TB Alliance to develop novel TB drug regimens

QIAGEN and DiaSorin launch automated, CE-marked workflow for high-throughput TB screening

Inhaled steroid use linked to greater risk of NTM lung infections

Scientists develop first non-antibiotic drug to treat tuberculosis in animals

Effective vaccines for world's most prevalent infectious diseases are missing from pipeline

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Tuberculosis News and Research

Latest Tuberculosis News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in